Monomeric CRP is Elevated in Patients with COPD Compared to Non-COPD Control Persons

R. Munuswamy, J. De Brandt, C. Burtin, W. Derave, J. Aumann, M.A. Spruit, L. Michiels*

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

4 Citations (Web of Science)


Chronic low-grade systemic inflammation is frequently observed in patients with chronic obstructive pulmonary disease (COPD), e.g., elevated pentameric CRP (pCRP). However, pCRP can dissociate to form monomeric CRP (mCRP) which exhibits a clear pro inflammatory behaviour in contrast to the more anti-inflammatory properties of pCRP. Therefore, mCRP may be an informative biomarker to demonstrate chronic low-grade systemic inflammation. This was confirmed by analysing serum samples from 38 patients with COPD and 18 non-COPD control persons (NCCP). mCRP was significantly elevated in patients with COPD vs. NCCP, indicating that mCRP might be considered as a new sensitive marker of chronic low-grade systemic inflammation.
Original languageEnglish
Pages (from-to)4503-4507
Number of pages5
JournalJournal of Inflammation Research
Publication statusPublished - 2021


  • COPD
  • low-grade systemic inflammation
  • pCRP
  • mCRP

Cite this